Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614122 | 1.00 | DPP4 (0.67) | DPP4CYP2D6SRCLMNAMAPK1 | |
| Cadaverine Tartrate SCHEMBL30110790 | 0.84 | DPP4 (0.64) | DPP4CYP2D6SRCLMNAMAPK1 | |
| Oxalic Acid SCHEMBL10632513 | 0.83 | DPP4 (0.70) | DPP4CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL304041 | 0.82 | TDP1 (0.47) | DPP4CYP2D6SRCLMNASLC1A2 | |
| SCHEMBL6046193 | 0.82 | TDP1 (0.47) | DPP4CYP2D6SRCLMNASLC1A2 | |
| SCHEMBL16826249 | 0.82 | TDP1 (0.47) | DPP4CYP2D6SRCLMNASLC1A2 | |
| SCHEMBL851654 | 0.82 | DPP4 (1.00) | DPP4LMNAF2 | |
| SCHEMBL644767 | 0.82 | DPP4 (1.00) | DPP4LMNAF2 | |
| SCHEMBL1878642 | 0.82 | DPP4 (1.00) | DPP4LMNAF2 | |
| SCHEMBL239938 | 0.82 | DPP4 (1.00) | DPP4LMNAF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024215515-A1 | DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024178310-A1 | TROP2-DIRECTED ANTIBODY-DRUG CONJUGATES AND USES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| WO-2024178360-A2 | AURISTATIN ANALOGS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| EP-4598586-A1 | DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF | Ambrx, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| CN-112840030-B | Method for reducing nitrosamine content in tobacco using constitutive high affinity cationic efflux proteins | 英美烟草(投资)有限公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2025041055-A1 | ANTI-PSMA ADC CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | AMBRX, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2024241086-A1 | PEGYLATED BOVINE INTERFERON LAMBDA AND METHODS OF USE THEREOF | AMBRX, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024215515-A1 | DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024178360-A2 | AURISTATIN ANALOGS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024178310-A1 | TROP2-DIRECTED ANTIBODY-DRUG CONJUGATES AND USES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024077277-A1 | DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20020165162-A1 | Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases | BIO-RAD LABORATORIES, INC. | 2002-11-07 | — | — | US | disclosed |
| US-6455550-B1 | INHIBITORS OF BINDING BETWEEN VASCULAR CELL ADHESION MOLECULES AND CELLS EXPRESSING VLA-4 INTEGRIN; ANTIINFLAMMATORY AGENTS | HOFFMANN-LA ROCHE INC. | 2002-09-24 | — | — | US | disclosed |
| US-6229011-B1 | BINDING INHIBITORS BETWEEN VASCULAR ADHESION MOLECULE-1 AND ALPHA. BETA.INTEGRIN; USEFUL FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES SUCH AS MULTIPLE SCLEROSIS, ASTHMA, AND INFLAMMATORY BOWEL DISEASE | HOFFMAN-LA ROCHE INC. | 2001-05-08 | — | — | US | disclosed |
| CN-1276785-A | N-aroylphenylalanine derivs. | HOFFMANNN LA ROCHE AG F (CH) | 2000-12-13 | — | — | CN | disclosed |
| EP-1005446-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| EP-1005445-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010312-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010313-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
| WO-1992001462-A1 | AMPHIPHILIC PEPTIDE COMPOSITIONS AND ANALOGUES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 1992-02-06 | — | — | WO | disclosed |